SMSLIFE.NS Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: October 22, 2025
Report Source: 2026 1st Quarter Report
Haleos Labs Ltd. Stock Analysis SMSLIFE.NS
SMS Lifesciences India Ltd. engages in manufacturing and selling of active pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2017-08-17. The firm's API products include Ranitidine Hydrochloride (Form-2) USP / Ph. Eur / IP, Famotidine USP / Ph. Eur / IP, Sildenafil Citrate USP / Ph. Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph. Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. Its intermediate offerings include Ranitidine HCl Intermediates, Rizatriptan Intermediates and Imidapril Intermediates. The firm's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center is at Sanath Nagar in Hyderabad. The firm's wholly owned subsidiary is Mahi Drugs Private Limited.
Read More Haleos Labs Ltd (SMSLIFE.NS) Chart
Key Statistics of Haleos Labs Ltd (SMSLIFE.NS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
₹1,262.00Volume
602.00P/E Ratio (TTM)
20.2852 Week Range
Market Cap
3.72BAvg. Volume
714.33Dividend Yield
0.11%Financial Metrics & Statements of Haleos Labs Ltd (SMSLIFE.NS)
FAQ's for Haleos Labs Ltd (SMSLIFE.NS)
- According to Musaffa’s Shariah screening methodology, Haleos Labs Ltd (SMSLIFE.NS) is currently classified as NOT HALAL as of October 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.